Skip to main content

Day: June 17, 2020

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical CenterATI-450 Inhibits Multiple Key Inflammatory CytokinesWAYNE, Pa., June 17, 2020 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that the FDA has allowed an investigational new drug application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19.  Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome (CRS) in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug supply to the University...

Continue reading

Cramo Plc announces an increase in the Tender Consideration for its notes due 2022

Cramo Plc          Inside Information          17 June 2020 at 2.15 pm Finnish time (EET)Cramo Plc announces an increase in the Tender Consideration for its notes due 2022NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.Capitalized terms used herein shall have the meaning ascribed to them in the Consent Solicitation and Tender Offer Memorandum (as defined below).Cramo Plc (“Cramo“) has on 12 June 2020 invited all holders (the “Noteholders“) of its outstanding EUR 150,000,000 2.375 % notes due 2022 (ISIN: FI4000232509) with a current outstanding amount of EUR 134,200,000 (the...

Continue reading

Cramo korottaa vuonna 2022 erääntyvien joukkovelkakirjojen takaisinostohintaa

Cramo Oyj            Sisäpiiritieto         17.6.2020 klo 14.15Cramo korottaa vuonna 2022 erääntyvien joukkovelkakirjojen takaisinostohintaaEI JULKAISTAVAKSI TAI LEVITETTÄVÄKSI, KOKONAAN TAI OSITTAIN, SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA, HONGKONGISSA, JAPANISSA, UUDESSA-SEELANNISSA, SINGAPORESSA TAI ETELÄ-AFRIKASSA TAI MISSÄÄN MUUSSA VALTIOSSA, JOSSA JULKAISEMINEN TAI LEVITTÄMINEN OLISI LAINVASTAISTACramo Oyj (“Cramo“) tiedotti 12.6.2020 kutsuvansa sen vuonna 2022 erääntyvien 150.000.000 euron 2,375 % ulkona olevien joukkovelkakirjojen (ISIN: FI4000232509) (“Joukkovelkakirjat“) haltijat (“Joukkovelkakirjanhaltijat“) myymään Joukkovelkakirjansa käteistä vastaan Cramolle 12.6.2020 päivätyssä englanninkielisessä tarjousmuistiossa (“Tarjousmuistio“) esitettyjen ehtojen...

Continue reading

Clearside Biomedical Announces Numerous Presentations at the ARVO 2020 Meeting

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration –– Evidence supports the reliability, repeatability, and consistency of Clearside’s suprachoroidal injection procedure for chorio-retinal diseases using patented SCS Microinjector® –ALPHARETTA, Ga., June 17, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) are available online at the ARVO 2020 Meeting.Due to COVID-19, the ARVO 2020 Annual Meeting is being held virtually.  As a result,...

Continue reading

Wisdomtree Brent Crude Oil 3x Daily Short Securities Proposed Amendment to the Principal Amount of the Affected Securities Meeting of the Etp Security Holders

17 June 2020LEI: 2138003QW2ZAYZODBU23LSE Code: 3BRSWISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE BRENT CRUDE OIL 3X DAILY SHORT SECURITIESPROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIESMEETING OF THE ETP SECURITY HOLDERSTHIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser.If you have sold or transferred all of your WisdomTree Brent Crude Oil 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or stockbroker, banker or...

Continue reading

OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics. A product of OraSure’s DNA Genotek subsidiary, the OMNImet™·GUT (ME-200) augments the Company’s portfolio of multiomic sample collection products.  The device is intended for research use only.“Advances in the prediction, detection, understanding, and monitoring of human diseases have increased the use of metabolomics technologies,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek. “OMNImet™·GUT is designed to help scientists efficiently unlock the...

Continue reading

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1700 (rTFF2) will be presented in a poster at the American Association of Cancer Research (AACR) Virtual Annual Meeting II. The meeting is being held June 22-24, 2020.Details of poster presentation at AACR 2020:Title:  Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancerAuthors: Woosook Kim, Na Fu, Phaneendra Duddempudi, Zinaida Dubeykovskaya, Steven Almo, Chandan Guha, Seth Lederman, and Timothy WangPoster Session: Combination Immunotherapies 4Date and Time:  Monday, June 22, 2020, 9:00 a.m. – 6:00 p.m. ETAbout Tonix Pharmaceuticals Holding...

Continue reading

Election of the Chairman and Vice-Chairman of the Supervisory Board of Coop Pank AS, changes in composition of the Audit Committee and Remuneration Committee

At the meeting of the Supervisory Board of Coop Pank AS, held on 17.06.2020, Alo Ivask was appointed as the new Chairman of the Supervisory Board of the company and Ardo Hillar Hansson was appointed as the new Vice-Chairman of the Supervisory Board of the company, both positions starting from 17.06.2020.The Supervisory Board of Coop Pank AS also recalled the following persons from the Audit Committee: Jaanus Vihand, Priit Põldoja and Märt Meerits. The Supervisory Board elected the following members to the Audit Committee effective from 17.06.2020: Alo Ivask, Silver Kuus and Urmas Kaarlep. The current Chairman of the Audit Committee, Paavo Truu, will continue as the Chairman of the Audit Committee.Changes also took place in the Remuneration Committee. The following persons were recalled from from the Remuneration Committee: Jaanus Vihand...

Continue reading

Coop Pank AS nõukogu esimehe ja aseesimehe valimine, muudatused auditikomitee ja töötasukomitee koosseisus

17.06.2020 toimunud Coop Pank AS-i nõukogu koosolekul nimetati alates 17.06.2020 ettevõtte uueks nõukogu esimeheks Alo Ivask, ning aseesimeheks Ardo Hillar Hansson.  Ühtlasi kutsus Coop Pank AS auditikomiteest tagasi järgnevad isikud: Jaanus Vihand, Priit Põldoja ja Märts Meerits. Nõukogu valis alates 17.06.2020 uuteks auditikomitee liikmeteks järgnevad isikud: Alo Ivask, Silver Kuus ja Urmas Kaarlep. Auditikomitee esimehena jätkab senine auditikomitee esimees Paavo Truu.Samuti toimusid muudatused töötasukomitees. Töötasukomiteest kutsuti tagasi järgnevad isikud: Jaanus Vihand ja Priit Põldoja. Nõukogu valis alates 17.06.2020 uuteks töötasukomitee liikmeteks järgnevad isikud: Alo Ivask, Raul Parusk ja Irja Rae. Töötasukomitee liikmena jätkab senine liige Jaanus Marjundi.Eesti kapitalil põhinev Coop Pank on üks viiest Eestis tegutsevast...

Continue reading

ValOre Provides Exploration Update for Pedra Branca PGE Project and Initiates Metallurgical Testwork

VANCOUVER, British Columbia, June 17, 2020 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSX‐V: VO; OTCQX: KVLQF; FRANKFURT: KEQ0) today announced results from 54 grab samples, provided an update on the Mendes North geochemical sampling program, and commenced the initiation of a metallurgical testwork program for ValOre’s 100%-owned Pedra Branca Platinum Group Elements Project (“PGE”), located near the community of Capitão Mór in northeastern Brazil.Key Updates on ValOre’s 2020 Pedra Branca PGE Exploration Program:“2PGE+Au” (being palladium (Pd), platinum (Pt) and gold (Au)) assay results have been received for 54 property-wide rock samples, with the highest grade sample exceeding 26 g 2PGE+Au/t, 4 samples >10 g 2PGE+Au/t, 6 samples ranging from 5-10 g 2PGE+Au/t, and an additional 27 samples returning anomalous 2PGE+Au grades;598...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.